The company's products are designed to facilitate medical imaging and clinical research, with a focus on advancing patient care by providing diagnostic and therapeutic radioisotopes, novel radiopharmaceuticals and customized radiopharmaceutical development services. NorthStar is the only commercial U.S. producer of the important diagnostic imaging radioisotope molybdenum-99 (Mo-99), used to assess heart disease and cancer for 40,000 U.S. patients daily. The company is also expanding its production capabilities to meet anticipated increased demand and is poised to be the first commercial-scale producer of non-carrier-added (n.c.a.) actinium-225 (Ac-225) and copper-67 (Cu-67), using first-in-kind and environmentally preferable, electron accelerator technology. Additionally, NorthStar offers customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies advance their development and commercialization programs.